R&G PharmaStudies Co. Ltd. A (301333) - Cash Flow Conversion Efficiency
Based on the latest financial reports, R&G PharmaStudies Co. Ltd. A (301333) has a cash flow conversion efficiency ratio of 0.090x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥40.98 Million ≈ $6.00 Million USD) by net assets (CN¥454.13 Million ≈ $66.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
R&G PharmaStudies Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how R&G PharmaStudies Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read R&G PharmaStudies Co. Ltd. A total liabilities for a breakdown of total debt and financial obligations.
R&G PharmaStudies Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of R&G PharmaStudies Co. Ltd. A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baotou Huazi Industry Co Ltd
SHG:600191
|
0.016x |
|
ABCELLERA BIOLOGICS
F:8QQ
|
-0.036x |
|
Asuransi Jiwa Sinarmas Msig PT
JK:LIFE
|
0.023x |
|
Allied Properties Real Estate Investment Trust
TO:AP-UN
|
0.029x |
|
LGI Homes
NASDAQ:LGIH
|
0.041x |
|
Ningbo Runhe High-Tech Materials Co Ltd Class A
SHE:300727
|
0.061x |
|
Jiangsu Baichuan HighTech New Materials Co Ltd
SHE:002455
|
0.059x |
|
Zhejiang China Light & Textile Industrial City Group Co Ltd
SHG:600790
|
-0.007x |
Annual Cash Flow Conversion Efficiency for R&G PharmaStudies Co. Ltd. A (2019–2024)
The table below shows the annual cash flow conversion efficiency of R&G PharmaStudies Co. Ltd. A from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see R&G PharmaStudies Co. Ltd. A (301333) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.84 Billion ≈ $268.68 Million |
CN¥154.76 Million ≈ $22.65 Million |
0.084x | -23.20% |
| 2023-12-31 | CN¥1.75 Billion ≈ $256.76 Million |
CN¥192.56 Million ≈ $28.18 Million |
0.110x | +34.06% |
| 2022-12-31 | CN¥1.59 Billion ≈ $233.21 Million |
CN¥130.47 Million ≈ $19.09 Million |
0.082x | -68.72% |
| 2021-12-31 | CN¥437.81 Million ≈ $64.07 Million |
CN¥114.57 Million ≈ $16.77 Million |
0.262x | +99.97% |
| 2020-12-31 | CN¥336.98 Million ≈ $49.31 Million |
CN¥44.10 Million ≈ $6.45 Million |
0.131x | -68.41% |
| 2019-12-31 | CN¥249.74 Million ≈ $36.55 Million |
CN¥103.48 Million ≈ $15.14 Million |
0.414x | -- |
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It provides drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology … Read more